ArticleOxford medical case reports2025
A very rare cause of oliguric acute kidney disease: crescentic C3 glomerulopathy.
Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Crescentic glomerulonephritis, which is mostly recognized due to lupus nephritis, anti-neutrophil cytoplasmic antibody-associated vasculitis, anti-glomerular basement membrane antibody disease, and immune complex-mediated injury, complicates acute kidney disease (AKD). Case description: A 37 year-old male patient with oligo-anuric AKD who developed indications for renal replacement therapy secondary to crescentic complement 3 (C3) glomerulopathy was presented. Endocapillary necrotizing crescentic glomerulonephritis with isolated C3 deposition in the kidney biopsy of our patient was confirmed as complement 3 glomerulopathy (C3G). The patient was successfully treated with oral methylprednisolone and 6 doses of monthly parenteral cyclophosphamide. Conclusion: We emphasize the importance of proteinuria evaluation in patients with oligo-anuric AKD even when polyuria phase begins which means that the recovery period of AKD is initiated. Therefore, crescentic C3G should be considered in such patients. Monoclonal gammopathy and genetic factor H defects should be investigated to determine the underlying etiology in C3G patients. Monthly cycles of cyclophosphamide infusion (a total of 6 cycles) are beneficial for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.